| P2093 | author name string | Chaddock John | |
| | Foster Keith | |
| P2860 | cites work | Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications | Q81421439 |
| | Botulinum toxin products overview | Q82022191 |
| | Recovery from botulinum neurotoxin poisoning in vivo | Q82612352 |
| | Botulism | Q21994439 |
| | Botulinum Toxin as a Biological Weapon: Medical and Public Health Management | Q23832736 |
| | Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues | Q24321205 |
| | Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation | Q27653311 |
| | Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A | Q27654586 |
| | Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype F | Q27655649 |
| | Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B | Q27665891 |
| | Crystal structure of botulinum neurotoxin type A and implications for toxicity | Q27765727 |
| | Reconstituted membrane fusion requires regulatory lipids, SNAREs and synergistic SNARE chaperones | Q27931637 |
| | SNAP receptors implicated in vesicle targeting and fusion | Q28131653 |
| | Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity | Q28254916 |
| | Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments | Q28609202 |
| | Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage | Q28609220 |
| | SNAREs--engines for membrane fusion | Q29547230 |
| | The mechanisms of vesicle budding and fusion | Q29615234 |
| | Clostridial neurotoxins: structure-function led design of new therapeutics | Q30231439 |
| | The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction | Q31036598 |
| | Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain | Q33301010 |
| | Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system | Q33712120 |
| | Neurotoxins affecting neuroexocytosis | Q33881286 |
| | OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program | Q34116531 |
| | Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons | Q34154552 |
| | Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery | Q34282549 |
| | Treatment of Glabellar Frown Lines with C. Botulinum-A Exotoxin | Q34615234 |
| | Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q34776040 |
| | What is the role of SNARE proteins in membrane fusion? | Q35169800 |
| | Evidence for antinociceptive activity of botulinum toxin type A in pain management | Q35187501 |
| | Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. | Q35250681 |
| | Genetic diversity among Botulinum Neurotoxin-producing clostridial strains | Q35634548 |
| | Identification of the major steps in botulinum toxin action | Q35639122 |
| | Botulinum toxin in clinical practice | Q35807826 |
| | Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells | Q36325534 |
| | Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. | Q36373708 |
| | Botulinum neurotoxin - from laboratory to bedside | Q36511588 |
| | Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons | Q36639118 |
| | From poison to remedy: the chequered history of botulinum toxin | Q36801432 |
| | Future aspects of botulinum neurotoxins | Q36844148 |
| | Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. | Q36992893 |
| | Botulinum toxin drugs: future developments | Q37117645 |
| | Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q37155197 |
| | Engineering botulinum neurotoxin to extend therapeutic intervention. | Q37224285 |
| | Botulinum neurotoxins in the treatment of refractory pain | Q37337947 |
| | Disease-oriented approach to botulinum toxin use. | Q37346370 |
| | Engineered toxins: new therapeutics | Q37407389 |
| | NeuroBloc/Myobloc: unique features and findings | Q37414847 |
| | Development of future indications for BOTOX. | Q37496204 |
| | Botulinum neurotoxin: a marvel of protein design | Q37710092 |
| | Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects | Q37749805 |
| | Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A | Q39515519 |
| | Reconstitution of Rab- and SNARE-dependent membrane fusion by synthetic endosomes. | Q39848704 |
| | SV2 is the protein receptor for botulinum neurotoxin A. | Q40303506 |
| | Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential | Q42452235 |
| | The changed image of botulinum toxin | Q42780619 |
| | Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present | Q42800833 |
| | Catalytic properties of botulinum neurotoxin subtypes A3 and A4. | Q43106828 |
| | Intragastric injection of botulinum toxin for the treatment of obesity. Where are we? | Q43107739 |
| | The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking | Q43669503 |
| | Membrane Interaction of botulinum neurotoxin A translocation (T) domain. The belt region is a regulatory loop for membrane interaction. | Q43960895 |
| | Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia | Q44394591 |
| | Proteolysis of synthetic peptides by type A botulinum neurotoxin | Q44592997 |
| | Subcutaneous administration of botulinum toxin A reduces formalin-induced pain | Q44722571 |
| | Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain | Q44803129 |
| | Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. | Q44881077 |
| | Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy | Q46294932 |
| | Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. | Q46644837 |
| | Substrate recognition strategy for botulinum neurotoxin serotype A. | Q46801352 |
| | Translocation of botulinum neurotoxin light chain protease through the heavy chain channel | Q46942366 |
| | Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics | Q47783055 |
| | Different types of botulinum toxin in humans | Q47935598 |
| | The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. | Q50753274 |
| | Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. | Q50755840 |
| | Xeomin is free from complexing proteins. | Q51764777 |
| | Uptake of botulinum neurotoxin into cultured neurons. | Q52095157 |
| | The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. | Q52312776 |
| | Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. | Q52861424 |
| | History of the cosmetic use of Botulinum A exotoxin. | Q53565450 |
| | Mechanism of substrate recognition by botulinum neurotoxin serotype A. | Q53575621 |
| | Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. | Q54541506 |
| | How do tetanus and botulinum toxins bind to neuronal membranes? | Q56226691 |
| | SNAREs and traffic | Q56850814 |
| | SNARE motif and neurotoxins | Q59098553 |
| | Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction | Q66829168 |
| | Cooperative action of the light chain of tetanus toxin and the heavy chain of botulinum toxin type A on the transmitter release of mammalian motor endplates | Q68305272 |
| | Tetanus toxin in dissociated spinal cord cultures: long-term characterization of form and action | Q69572834 |
| | Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery | Q71162398 |
| | Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study | Q72649948 |
| | A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells | Q73009327 |
| | A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro | Q73043502 |
| | Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins | Q73426186 |
| | Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms | Q73634933 |
| | Spectroscopic analysis of pH-induced changes in the molecular features of type A botulinum neurotoxin light chain | Q73829099 |
| | Persistence of botulinum neurotoxin action in cultured spinal cord cells | Q78144026 |
| | Influence of nerve‐ending activity and of drugs on the rate of paralysis of rat diaphragm preparation by Cl. botulinum type A toxin | Q78931830 |
| | Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F | Q79753944 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P921 | main subject | enzyme | Q8047 |
| | bacterial protein | Q64923821 |
| P304 | page(s) | 2795-2815 | |
| P577 | publication date | 2010-12-01 | |
| | 2010-12-03 | |
| P1433 | published in | Toxins | Q15724569 |
| P1476 | title | Targeted secretion inhibitors-innovative protein therapeutics | |
| P478 | volume | 2 | |